Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Apellis was largely as anticipated with the company preannouncing key results in January, the firm notes. Management anticipates flat Syfovre pricing into FY26 and more limited growth. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on APLS: Dis ...

Management characterizes 2025 as a foundational year of disciplined execution, focusing on the central role of C3 inhibition to address complement-driven diseases across ophthalmology and nephrology. SYFOVRE performance in geographic atrophy (GA) is described as resilient, with 17% year-over-year growth in total injections despite revenue being impacted by elevated free goods utilization. The EMPAVELI launch in C3G and primary IC-MPGN is cited as a primary near-term growth engine, achieving over 5% ma ...

Management discussed recent changes in co-pay assistance availability. CEO Cedric Francois said third-party co-pay assistance programs began reopening to new patients and that the company was encouraged by the potential for improved access, though it did not have visibility into how quickly activity might ramp. In Q&A, Sullivan said the reopening is “an important advance” for patients who have been unable to pay, but Apellis could not yet quantify the impact on free goods trends.Executive Vice President of ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Kura Oncology, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - Kura Oncology is expected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of -227.3% [3] - Revenues are projected to be $29.81 million, down 44.7% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 552.38% lower in the last 30 days, indicating a significant reassessment by analysts [4] - The Most Accurate Estimate for Kura Oncology is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.29% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with predictive power being significant for positive readings only [9][10] - Kura Oncology currently holds a Zacks Rank of 4, complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Kura Oncology was expected to post a loss of $0.57 per share but actually reported a loss of -$0.85, resulting in a surprise of -49.12% [13] - Over the past four quarters, Kura has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Apellis Pharmaceuticals is expected to report a loss of $0.39 per share, indicating a year-over-year change of -34.5% [18] - Apellis' revenue is projected to be $194.37 million, down 8.5% from the previous year, with an Earnings ESP of -3.07% [19][20]

Core Insights - Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases using its proprietary TransCon technology for long-acting prodrugs [1] - The company faces challenges in capital efficiency, as indicated by its negative return on invested capital (ROIC) [1] Financial Metrics - Ascendis Pharma's ROIC is -18.95%, significantly lower than its weighted average cost of capital (WACC) of 5.88%, indicating insufficient returns to cover capital costs [2] - In contrast, argenx SE has a ROIC of 7.68% and a WACC of 4.55%, resulting in a ROIC to WACC ratio of 1.69, demonstrating effective capital utilization [3] - Apellis Pharmaceuticals, Inc. also shows efficient capital use with a ROIC of 8.81% and a WACC of 5.31%, leading to a ROIC to WACC ratio of 1.66 [4] - Blueprint Medicines Corporation shares a similar challenge with Ascendis, having a negative ROIC of -13.09% against a WACC of 8.26%, highlighting inefficiencies in capital utilization [5]

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

Core Viewpoint - Apellis Pharmaceuticals Inc. is recognized as a high short interest stock with significant upside potential, particularly due to the promising commercial prospects of its drug Empaveli in treating rare kidney diseases [1]. Group 1: Analyst Ratings and Price Targets - Bank of America upgraded Apellis to Buy from Neutral with an unchanged price target of $28, emphasizing the market's undervaluation of Empaveli's commercial prospects [1]. - Wells Fargo reduced its price target for Apellis to $26 from $29 while maintaining an Overweight rating, citing a slower-than-expected commercial ramp for Empaveli in specific indications [2]. Group 2: Revenue Estimates and Market Potential - Bank of America has cut its revenue estimates for 2026–2030 by 20% to 50% to reflect a more gradual adoption curve for Empaveli, while estimates for another drug, Syfovre, remain largely unchanged [3]. - The initial 5% penetration of the 5,000-patient US market for Empaveli has led analysts to forecast continued financial upside as the drug expands into new indications [1]. Group 3: Company Overview - Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic compounds to address diseases with high unmet needs [4].

分组1 - Sherry Paul from Morgan Stanley discusses market volatility, emphasizing it as a normal part of investing and indicating a shift from the 'Magnificent Seven' to 'magnificent thematics' such as AI automation and innovation [1][2] - The MAG7 companies are evolving into diversified holding companies, with traditional sector labels becoming distorted as tech firms venture into new industries [2] - Paul recommends an equal-weight approach for ETF investors to avoid over-concentration in mega-cap stocks and suggests focusing on the remaining 473 stocks in the S&P 500 for investment opportunities [2] 分组2 - Apellis Pharmaceuticals Inc. (NASDAQ:APLS) has an average upside potential of 47.33%, with Bank of America upgrading its rating to Buy, citing undervalued prospects for its drug Empaveli in treating rare kidney diseases [7][8] - Wells Fargo has reduced its price target for Apellis to $26 from $29, reflecting a slower-than-expected commercial ramp for Empaveli, while cutting revenue estimates for 2026-2030 by 20% to 50% [9][10] - Vera Therapeutics Inc. (NASDAQ:VERA) shows an average upside potential of 55.09%, with Bank of America raising its price target from $48 to $66 due to increased revenue forecasts for its lead drug [11][12] - Goldman Sachs and JPMorgan have also raised their price targets for Vera Therapeutics, reflecting a broader market potential and positive developments in its drug pipeline [12][13]

Index Changes - S&P Dow Jones Indices will implement changes to the S&P MidCap 400 and S&P SmallCap 600 indices effective January 30 and February 2, 2026 [1][3] - TTM Technologies (TTMI) will be added to the S&P MidCap 400, replacing Civitas Resources (CIVI), which is being acquired by SM Energy [1][3] - Amneal Pharmaceuticals (AMRX) will be added to the S&P SmallCap 600, replacing TTM Technologies [1][3] - Dutch Bros (BROS), Advanced Energy Industries (AEIS), and American Healthcare REIT (AHR) will be added to the S&P MidCap 400 on February 2, 2026, with Comerica (CMA), Cadence Bank (CADE), and PotlatchDeltic (PCH) being removed [1][3] - Apellis Pharmaceuticals (APLS) and LegalZoom.com (LZ) will be added to the S&P SmallCap 600, replacing Advanced Energy Industries and Elme Communities (ELME), respectively [1][3] Acquisition Details - SM Energy is acquiring Civitas Resources, and the deal is expected to close soon, with SM Energy remaining in the S&P SmallCap 600 post-merger [3] - Rayonier is acquiring PotlatchDeltic, and will remain in the S&P MidCap 400 after the merger [3] - Fifth Third Bancorp is acquiring Comerica, which will also remain in the S&P MidCap 400 post-acquisition [3] - Huntington Bancshares is acquiring Cadence Bank, with Cadence being removed from the S&P MidCap 400 [3] - Elme Communities is undergoing liquidation activities, making it no longer suitable for the S&P SmallCap 600 [3]

Core Insights - Apellis Pharmaceuticals' stock has decreased by 31% over the past year despite receiving FDA approval for EMPAVELI, indicating a disconnect between regulatory success and commercial performance [2][7] Product Approval and Market Potential - EMPAVELI is the first and only approved treatment for C3 glomerulopathy and IC-MPGN, targeting approximately 5,000 patients in the U.S., with exclusive approval for about two-thirds of this population [3] - The positive opinion from the European CHMP in December 2025 enhances the global expansion potential and pricing power, typically associated with gross margins exceeding 90% [3] Patient Start Forms and Growth Expectations - Management has guided for 225 cumulative patient start forms by the end of 2025, having achieved 152 by the end of September, suggesting a slowdown to 24 forms per month in Q4 [4] - CEO Cedric Francois indicated that the company is moving past the initial wave of early adopters and anticipates steady growth moving into the next year [4] Revenue Challenges and Market Dynamics - SYFOVRE, which constitutes the majority of revenue, reported flat sales of $151 million in Q3 2025, with a mere 4% growth in injections, primarily driven by free goods costing the company $15 million [5] - The share of new patients for SYFOVRE has decreased to 52%, with management noting that retina specialists are adopting a cautious approach despite SYFOVRE's 60% market share [5] External Market Issues - The cessation of new co-pay assistance applications by Good Days Foundation has led to practices halting new patient enrollments, a challenge not unique to Apellis but reflective of broader issues in the geographic atrophy market [6]